Κετίκογλου Ιωάννης

Πτυχίο Ιατρικής

Ιατρική Σχολή Παν/μίου Αθηνών, 1970-1976

Ειδικευόμενος  Παθολογίας, 3^ο Θεραπευτήριο ΙΚΑ Δ/ντης κ. Λ. Σπάρος, 1980-1985

• Εξάμηνη εκπαίδευση στην υπερηχογραφία   κοιλίας (υπό την καθοδήγηση του Επικούρου Καθηγητού κ. Α. Δαδιώτη) 

• 1^ο Βραβείο  Καλύτερης  Αναρτημένης  Ανακοίνωσης με θέμα «Προγνωστική  σημασία  του τρόπου μετάδοσης  ηπατίτιδας C  σε σχέση  με  την απάντηση  στην  αγωγή με Ιντερφερόνη» .Πανελλήνιο Συνέδριο Γαστρεντερολογίας, 1997
• Βραβείο Καλύτερης Ηπατολογικής Εργασίας με θέμα «Στεάτωση σε χρόνια ηπατίτιδα C  σε  συσχέτιση  με το βαθμό ίνωσης  και γονότυπο . Βραβείο Γεράσιμος  Καρβουντζής 2003.
• 1^ο  Βραβείο στην  εργασία με  θέμα  « Αποτελεσματικότητα  της  ιντερφερόνης α2α σε       ασθενείς με χρόνια  ηπατίτιδα C και συμπτωματική κρυοσφαιριναιμία» 9^ο  Πανελλήνιο   συνέδριο Παθολογίας  2003
• Βραβείο Γεράσιμος Καρβουντζής με θέμα «Επιδείνωση αγγειακών παραμέτρων σε ασθενείς με χρόνια ηπατίτιδα C κατά και μετά την αντιϊική θεραπεία με  πεγκυλιωμένη  ιντερφερόνη  και  ριμπαβιρίνη. 43 ο  Πανελλήνιο Ιατρικό  συνέδριο,  2017

• Ελληνική Εταιρεία Μελέτης του Ήπατος
• Μέλος της Επιτροπής Ιογενών Ηπατιτίδων του ΚΕΕΛΠΝΟ, 2005  –  Σήμερα

.    ΠΛΗΡΕΙΣ ΞΕΝΕΣ ΔΗΜΟΣΙΕΥΣΕΙΣ

1. Low rates of HBV serology testing in patients with chronic hepatitis C receiving direct acting antivirals. Dimitroglou J, Zampetas D, Vasilieva L, Koullias E, Ketikoglou I, Alexopoulou A, Dourakis SP. Aliment Pharmacol Ther 2017;46:908-909 (Letter).
2. Circulating autoantibodies to endogenous erythropoietin are associated with chronic hepatitis C virus infection-related anemia. Tsiakalos A, Voumvas T, Psarris A, Oikonomou CK, Ziogas DC, Ketikoglou I, Hatzis G, Sipsas NV. Hepatobiliary Pancreat Dis Int 2017;16:289-295.
3. A Giant Renal Vein Aneurysm in a Patient with Liver Cirrhosis. Filis K, Galyfos G, Ketikoglou Case Rep Med 2016;2016:8751310. Epub 2016 Sep 6.
4. Association of antiviral therapy with reduced disease progression in chronic Hepatitis B patients: Results from a nation-wide cohort study. Vourli G, Papatheodoridis G, Raptopoulou M, Dalekos GN, Hounta A, Nikolopoulou G, Zouboulis-Vafeiadis I, Manesis E, Kitis G, Gogos C, Ketikoglou I, Hatzis G, Vasilialdis T, Karatapanis S, Mimidis K, Drakoulis C, Touloumi G, The Hepnet-Greece. Hippokratia. 2016 Jul-Sep;20(3):214-221.
5. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group. PLoS One 2016;11:e0151703.
6. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. Cholongitas E, Papatheodoridis GV, Goulis J, Vlachogiannakos J, Karatapanis S, Ketikoglou J, Vasiliadis T, Kontos G, Karlaftis A, Akriviadis E. Ann Gastroenterol 2015;28:109-117.
7. Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. Anagnostou O, Manolakopoulos S, Bakoyannis G, Papatheodoridis G, Zisouli A, Raptopoulou-Gigi M, Manesis E, Ketikoglou I, Dalekos G, Gogos C, Vassiliadis T, Tzourmakliotis D, Karatapanis S, Kanatakis S, Zoumpoulis-Vafiadis I, Hounta A, Koutsounas S, Giannoulis G, Tassopoulos N, Touloumi G. Hippokratia 2014;18:57-64.
8. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN; HepNet.Greece Study Group. J Viral Hepat 2015;22:120-7.
9. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin. Striki A, Manolakopoulos S, Deutsch M, Mela M, Kalafateli M, Schini M, Anagnostou O, Triantos C, Andreadis I, Ketikoglou I, Papatheodoridis G, Pectasides D. J Viral Hepat 2014;21:624-632.
10. Listeria monocytogenes peritonitis: presentation, clinical features, treatment, and outcome. Liatsos GD, Thanellas S, Pirounaki M, KetikoglouI, Moulakakis A. Scand J Gastroenterol 2012;47:1129-1140 (Review).
11. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? Papastergiou V, Dimitroulopoulos D, Skorda L, Lisgos P, Ketikoglou I, Kostas N, Karatapanis S. J Med Virol 2012;84:1217-1223.
12. Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island. Karatapanis S, Tsoplou P, Papastergiou V, Vasiageorgi A, Stampori M, Saitis I, Tsitsopoulos E, Lisgos P, Skorda L, Ketikoglou I, Goulis I. J Med Virol 2012;84:223-228.
13. Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Manolakopoulos S, Striki A, Deutsch M, Mela M, KetikoglouI, Tzourmakliotis D, Manesis EK, Papatheodoridis GV. Liver Int 2011;31:1525-1532.
14. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK; HEPNET. Greece Cohort Study Group. Gut 2011;60:1109-1116.
15. Pegylated interferon alfa-2b pen device and ribavirin treatment for patients with chronic hepatitis C: an evaluation of patient satisfaction. Aggelopoulou-Tiga P, Dimitroulopoulos D, Kaligeros K, Koutsounas S, Kouroumalis E, Diamanti H, Ionnidou P, Kountouras J, Papaioannou C, Dimopoulou M, Giannoulis G, Ketikoglou I, Protopapas A, Bassaris H, Delis V, Karatapanis S, Manolakopoulos S, Mimidis K, Nikolaou A, Thomopoulos K, Tzelas G, Tsianos E, Kardasi M, Perperas A. Eur J Gastroenterol Hepatol 2010;22:1058-1065.
16. Possible green tea-induced thrombotic thrombocytopenic purpura. Liatsos GD, Moulakakis A, Ketikoglou I, Klonari S. Am J Health Syst Pharm 2010;67:531-534.
17. Hepatic parenchyma resection using stapling devices: peri-operative and long-term outcome.

Delis SG, Bakoyiannis A, Karakaxas D, Athanassiou K, Tassopoulos N, Manesis E, Ketikoglou I, Papakostas P, Dervenis C. HPB (Oxford) 2009;11:38-44.

18. Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study. Manesis EK, Papatheodoridis GV, Touloumi G, Karafoulidou A, Ketikoglou J, Kitis GE, Antoniou A, Kanatakis S, Koutsounas SJ, Vafiadis I; HEPNET.Greece Cohort Study. Aliment Pharmacol Ther 2009;29:1121-1130.
19. Epidemiology, course and disease burden of chronic hepatitis B virus infection. HEPNET study for chronic hepatitis B: a multicentre Greek study. Raptopoulou M, Papatheodoridis G, Antoniou A, Ketikoglou J, Tzourmakliotis D, Vasiliadis T, Manolaki N, Nikolopoulou G, Manesis E, Pierroutsakos I. J Viral Hepat 2009;16:195-202.
20. Patient’s age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Elefsiniotis IS, Pavlidis C, Ketikoglou I, Koutsounas S, Scarmeas N, Pantazis KD, Moulakakis A, Tsianos EV. Eur J Intern Med 2008;19:266-270.
21. Cytokeratin 8 and 18 expression in imprint smears of chronic viral hepatitis, autoimmune hepatitis and hepatocellular carcinoma. A preliminary study. Athanassiadou P, Psyhoyiou H, Grapsa D, Gonidi M, Ketikoglou I, Patsouris E. Acta Cytol 2007;51:61-65.
22. Changing serological status and low vaccination-induced protection rates against hepatitis B characterize chronic hepatitis C virus-infected injecting drug users in Greece: need for immunization policy. Elefsiniotis IS, Pantazis KD, Ketikoglou ID, Koutsounas SI, Tsianos EV. Eur J Gastroenterol Hepatol 2006;18:1227-1231.
23. Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. Mimidis K, Papadopoulos VP, Elefsiniotis I, Koliouskas D, Ketikoglou I, Paraskevas E, Kanatakis S, Chrysagis D, Dalekos GN, Tzathas C, Protopapas A, Gigi E, Tsianos E, Kartalis G. J Gastrointestin Liver Dis 2006;15:213-219.
24. Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment. Elefsiniotis IS, Petrocheilou A, Scarmeas N, Ketikoglou I, Pantazis KD, Toutouza M, Tsianos EV. J Clin Virol 2006;37:329-331.
25. Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment. Elefsiniotis IS, Vezali E, Kamposioras K, Pantazis KD, Tontorova R, Ketikoglou I, Moulakakis A, Saroglou G. World J Gastroenterol 2006;127:4420-4424.
26. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. Katsoulidou A, Sypsa V, Tassopoulos NC, Boletis J, Karafoulidou A, Ketikoglou I, Tsantoulas D, Vafiadi I, Hatzis G, Skoutelis A, Akriviadis E, Vasiliadis T, Kitis G, Magiorkinis G, Hatzakis A. J Viral Hepat 2006;13:19-27.
27. Serological profile of HBV infection and liver histopathology among injecting drug users with chronic HCV infection in Greece. Elefsiniotis IS, Hero B, Mariolis A, Pantazis KD, Fotos NV, Ketikoglou I, Saroglou G. Eur J Intern Med 2005;16:496-500.
28. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. Sypsa V, Touloumi G, Papatheodoridis GV, Tassopoulos NC, Ketikoglou I, Vafiadis I, Hatzis G, Tsantoulas D, Akriviadis E, Koutsounas S, Hatzakis A. J Viral Hepat 2005;12:543-550.
29. Autoimmune pancreatitis. Ketikoglou I, Moulakakis A. Dig Liver Dis 2005;37:211-215 (Review).
30. Relationship between serum b2-microglobulin levels and virological breakthrough in HBeAg-negative chronic hepatitis B patients, under long-term treatment schedules including lamivudine. Elefsiniotis IS, Moulakakis A, Pantazis KD, Glynou I, Ketikoglou I, Vezali E, Kada H, Tsianos E. World J Gastroenterol 2005;11:1922-1928.
31. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A. Eur J Dermatol 2005;15:107-10 9.
32. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. Papatheodoridis GV, Petraki K, Cholongitas E, Kanta E, Ketikoglou I, Manesis EK. J Viral Hepat 2005;12:199-206. Erratum in: J Viral Hepat. 2005 Jul;12(4):443.

33. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. Raptopoulou M, Tsantoulas D, Vafiadi I, Ketikoglou I, Paraskevas E, Vassiliadis T, Kanatakis S, Hatzis G, Sidiropoulos L, Akriviadis E. J Viral Hepat 2005;12:91-95.
34. Diabetes mellitus responsive to corticosteroids in autoimmune pancreatitis. Ketikoglou IG, Elefsiniotis IS, Vezali EV, Moulakakis AM. J Clin Gastroenterol 2004;38:910.
35. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. Sypsa V, Touloumi G, Tassopoulos NC, Ketikoglou I, Vafiadis I, Hatzis G, Tsantoulas D, Akriviadis E, Delladetsima J, Demonakou M, Hatzakis A. J Viral Hepat 2004;11:366-374.
36. Plasma pituitary adenylate cyclase activating polypeptide (PACAP) levels in chronic hepatitis B patients under lamivudine treatment. Elefsiniotis IS, Ketikoglou I, Kafiri G, Pantazis KD, Moulakakis A, Mavrogiannis C. Eur J Gastroenterol Hepatol 2003;15:1209-1216.
37. A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C. Tassopoulos NC, Ketikoglou I, Tsantoulas D, Raptopoulou M, Hatzis G, Vafiadis I, Sidiropoulos L, Kanatakis S, Anagnostopoulos G, Sypsa V, Hatzakis A; Hellenic Viral Hepatitis Research Network. J Viral Hepat 2003 Sep;10(5):383-9.
38. A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1. Tassopoulos NC, Tsantoulas D, Raptopoulou M, Vassiliadis T, Kanatakis S, Paraskevas E, Vafiadis I, Avgerinos A, Tzathas C, Manolakopoulos S, Ketikoglou I, Aggelis P, Goritsas K, Giannoulis G, Hatzis GG, Thomopoulos K, Akriviadis E, Sypsa V, Hatzakis A. J Viral Hepat 2003;10:189-196.
39. Interferon alfa-2b for decompensated liver disease caused by either chronic hepatitis B or C: preliminary results of a pilot study. Dimopoulou M, Fafoutis K, Basiliou K, Ketikoglou J, Karvountzis G. Gut 1993;34(2 Suppl):S104-5.

Ανακοινώσεις σε Ξένα Περιοδικά:   38

Ανακοινώσεις  σε  Ελληνικά Περιοδικά και Συνέδρια: 200

ΒΙΒΛΙΟΓΡΑΦΙΚΕΣ ΑΝΑΦΟΡΕΣ ΣΕ ΕΡΓΑΣΙΕΣ ΜΟΥ (citations ):   864

https://scholar.google.gr/citations?user=bw8HJzsAAAAJ&hl=en&citsig=AMD79opb0g46pMr5T3n655kmpmNxSFAB2A

1. Μεγάλη εμπειρία σε εκτέλεση βιοψιών ήπατος (~2000), είτε δια της κλασσικής διαδερματικής μεθόδου Menghini, είτε κατευθυνόμενες με χρήση υπερήχων.
2. Υπεύθυνος Εξωτερικού Ηπατολογικού Ιατρείου της Κρατικής Παθολογικής Κλινικής του Ιπποκρατείου νοσοκομείου  Αθήνας    επί  15 ετίαν

Τμήμα

• Ηπατολογικό

Επικοινωνία

Ευρωκλινική Αθηνών

Αθανασιάδου 7-9,  Αθήνα, ΤΚ 115 21

Τηλέφωνο: 210 6416040

Τηλέφωνο για ραντεβού: 210 6416040

Φαξ: 210 6416066